Otano, Itziar http://orcid.org/0000-0002-1433-1711
Azpilikueta, Arantza
Glez-Vaz, Javier http://orcid.org/0000-0001-8936-190X
Alvarez, Maite http://orcid.org/0000-0002-5969-9181
Medina-Echeverz, José
Cortés-Domínguez, Ivan
Ortiz-de-Solorzano, Carlos http://orcid.org/0000-0001-8720-0205
Ellmark, Peter
Fritzell, Sara
Hernandez-Hoyos, Gabriela
Nelson, Michelle Hase
Ochoa, María Carmen http://orcid.org/0000-0001-9920-2144
Bolaños, Elixabet
Cuculescu, Doina
Jaúregui, Patricia
Sanchez-Gregorio, Sandra
Etxeberria, Iñaki http://orcid.org/0000-0003-2713-0836
Rodriguez-Ruiz, María E.
Sanmamed, Miguel F.
Teijeira, Álvaro
Berraondo, Pedro http://orcid.org/0000-0001-7410-1865
Melero, Ignacio http://orcid.org/0000-0002-1360-348X
Funding for this research was provided by:
Cancer Research Institute (CRI-CLIP)
Article History
Received: 13 October 2020
Accepted: 11 November 2021
First Online: 15 December 2021
Competing interests
: I.M. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, Astra Zeneca, Numab, Catalym, and Bayer, and research funding from Roche, BMS, Alligator, and Bioncotech. P.B. reports advisory roles with Tusk and Moderna, research funding from Sanofi, and Bavarian Nordic and speaker honoraria from BMS, MSD, Novartis and AstraZeneca. J.M-E. is a full-time employee of Bavarian Nordic. P.E. and S.F. are employees at Alligator and G.H.H. is an employee at Aptevo. The rest of the authors declare no competing interests.